Richard C. Allsopp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richard C. Allsopp has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Calvin B. Harley
From the Beckman Center, Pathology Department, Stanford University School of Medicine, CA; Geron, Menlo Park, CA; and the Dana-Farber Cancer Institute, Harvard University, Boston, MA
1 shared publication- Gregg B. Morin
Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC, Canada
1 shared publication Irving L Weissman
Department of Pathology, Stanford University School of Medicine, Stanford, 94305, California, CA, USA
1 shared publicationIrving L. Weissman
From the Beckman Center, Pathology Department, Stanford University School of Medicine, CA; Geron, Menlo Park, CA; and the Dana-Farber Cancer Institute, Harvard University, Boston, MA
1 shared publication- Ronald Anthony DePinho
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication
Latest Publications
- Open Access
- 15 July 2003
- Published by American Society of Hematology in Blood
- Vol. 102 (2) , 517-520
Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation
Telomere shortening ultimately limits the replicative life span of cultured human somatic cells. Telomeres also shorten during replicative aging in vivo in hematopoietic cells, including early hematopoietic progenitors and hematopoietic stem cells (HSCs), from humans and mice, despite readily detectable levels of telomerase in these cells. To assess the relevance of telomerase to the long-term replicative capacity of HSCs in vivo, we serially transplanted HSCs from wild-type and telomerase-deficient mice until exhaustion and monitored telomere length in HSCs during this process. Telomerase-deficient HSCs could be serially transplanted for only 2 rounds, whereas wild-type HSCs could be serially transplanted for at least 4 rounds. Furthermore, the rate of telomere shortening was increased approximately 2-fold during serial transplantation of telomerase-deficient HSCs. These findings suggest that one role for telomerase in the HSC is to partially counter the rate of telomere shortening during division of HSCs, thereby preventing premature loss of telomere function and providing added replicative capacity.
- 15 July 2003
- Published by American Society of Hematology in Blood
- Vol. 102 (2) , 517-520
Open AccessTelomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation
Telomere shortening ultimately limits the replicative life span of cultured human somatic cells. Telomeres also shorten during replicative aging in vivo in hematopoietic cells, including early hematopoietic progenitors and hematopoietic stem cells (HSCs), from humans and mice, despite readily detectable levels of telomerase in these cells. To assess the relevance of telomerase to the long-term replicative capacity of HSCs in vivo, we serially transplanted HSCs from wild-type and telomerase-deficient mice until exhaustion and monitored telomere length in HSCs during this process. Telomerase-deficient HSCs could be serially transplanted for only 2 rounds, whereas wild-type HSCs could be serially transplanted for at least 4 rounds. Furthermore, the rate of telomere shortening was increased approximately 2-fold during serial transplantation of telomerase-deficient HSCs. These findings suggest that one role for telomerase in the HSC is to partially counter the rate of telomere shortening during division of HSCs, thereby preventing premature loss of telomere function and providing added replicative capacity.
- Open Access
- 13 May 2002
- Published by Springer Nature in Oncogene
- Vol. 21 (21) , 3270-3273
Replicative senescence of hematopoietic stem cells during serial transplantation: does telomere shortening play a role?
Hematopoietic stem cells (HSC) have a finite proliferative lifespan, based upon the limited number of times they can be serially transplanted in mice. Telomeres have been shown to shorten during the division of many normal somatic cells in humans, and the attrition of telomeres has been shown to ultimately cause replicative senescence in vitro for a number of different human cell strains. Whereas most human cell types have little to no detectable levels of telomerase activity, hematopoietic cells, including HSC, express low to moderate levels of telomerase, and yet telomeres shorten considerably during replicative aging of these cells. Here we consider the role telomerase may play in the hematopoietic system as well as the effect that over-expression of telomerase reverse transcriptase may have on the replicative capacity of hematopoietic stem cells during transplantation.
- 13 May 2002
- Published by Springer Nature in Oncogene
- Vol. 21 (21) , 3270-3273
Open AccessReplicative senescence of hematopoietic stem cells during serial transplantation: does telomere shortening play a role?
Hematopoietic stem cells (HSC) have a finite proliferative lifespan, based upon the limited number of times they can be serially transplanted in mice. Telomeres have been shown to shorten during the division of many normal somatic cells in humans, and the attrition of telomeres has been shown to ultimately cause replicative senescence in vitro for a number of different human cell strains. Whereas most human cell types have little to no detectable levels of telomerase activity, hematopoietic cells, including HSC, express low to moderate levels of telomerase, and yet telomeres shorten considerably during replicative aging of these cells. Here we consider the role telomerase may play in the hematopoietic system as well as the effect that over-expression of telomerase reverse transcriptase may have on the replicative capacity of hematopoietic stem cells during transplantation.